Metsera (NASDAQ:MTSR) Shares Down 6.1% – Should You Sell?

Metsera, Inc. (NASDAQ:MTSR)’s stock price traded down 6.1% during mid-day trading on Friday . The company traded as low as $25.18 and last traded at $25.29. 298,547 shares traded hands during mid-day trading, a decline of 48% from the average session volume of 579,270 shares. The stock had previously closed at $26.92.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued an “overweight” rating for the company. Evercore ISI assumed coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued an “outperform” rating for the company. Bank of America assumed coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued a “buy” rating and a $38.00 price target for the company. Finally, Guggenheim assumed coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued a “buy” rating and a $56.00 price target for the company.

Metsera Price Performance

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.